| The effect of the direct factor Xa inhibitors apixaban and rivaroxaban on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples R Bonar, EJ Favaloro, S Mohammed, M Ahuja, L Pasalic, J Sioufi, ... Pathology 48 (1), 60-71, 2016 | 119 | 2016 |
| Laboratory tests used to help diagnose von Willebrand disease: an update EJ Favaloro, L Pasalic, J Curnow Pathology 48 (4), 303-318, 2016 | 108 | 2016 |
| How to optimize activated partial thromboplastin time (APTT) testing: solutions to establishing and verifying normal reference intervals and assessing APTT reagents for … EJ Favaloro, G Kershaw, S Mohammed, G Lippi Seminars in thrombosis and hemostasis 45 (01), 022-035, 2019 | 106 | 2019 |
| Necrotic platelets provide a procoagulant surface during thrombosis VM Hua, L Abeynaike, E Glaros, H Campbell, L Pasalic, PJ Hogg, ... Blood, The Journal of the American Society of Hematology 126 (26), 2852-2862, 2015 | 98 | 2015 |
| Therapeutic monitoring of unfractionated heparin–trials and tribulations I Baluwala, EJ Favaloro, L Pasalic Expert Review of Hematology 10 (7), 595-605, 2017 | 78 | 2017 |
| Treatment of von Willebrand disease J Curnow, L Pasalic, EJ Favaloro Seminars in Thrombosis and Hemostasis 42 (02), 133-146, 2016 | 69 | 2016 |
| Laboratory testing for lupus anticoagulant (LA) in patients taking direct oral anticoagulants (DOACs): potential for false positives and false negatives EJ Favaloro, S Mohammed, J Curnow, L Pasalic Pathology 51 (3), 292-300, 2019 | 62 | 2019 |
| Current and emerging direct oral anticoagulants: state-of-the-art G Lippi, R Gosselin, EJ Favaloro Seminars in thrombosis and hemostasis 45 (05), 490-501, 2019 | 61 | 2019 |
| Laboratory monitoring or measurement of direct oral anticoagulants (DOACs): advantages, limitations and future challenges E J Favaloro, L Pasalic, J Curnow, G Lippi Current Drug Metabolism 18 (7), 598-608, 2017 | 61 | 2017 |
| Platelets in coronavirus disease 2019 JB Larsen, L Pasalic, AM Hvas Seminars in thrombosis and hemostasis 46 (07), 823-825, 2020 | 56 | 2020 |
| Clinical and laboratory diagnosis of heparin induced thrombocytopenia: an update EJ Favaloro, G McCaughan, L Pasalic Pathology 49 (4), 346-355, 2017 | 49 | 2017 |
| Novel assay demonstrates that coronary artery disease patients have heightened procoagulant platelet response L Pasalic, E Wing‐Lun, JK Lau, H Campbell, GJ Pennings, E Lau, ... Journal of Thrombosis and Haemostasis 16 (6), 1198-1210, 2018 | 48 | 2018 |
| Type 2M and type 2A von Willebrand disease: similar but different EJ Favaloro, L Pasalic, J Curnow Seminars in Thrombosis and Hemostasis, 483-497, 2016 | 48 | 2016 |
| HIT or miss? A comprehensive contemporary investigation of laboratory tests for heparin induced thrombocytopenia EJ Favaloro, G McCaughan, S Mohammed, KKE Lau, R Gemmell, ... Pathology 50 (4), 426-436, 2018 | 46 | 2018 |
| Platelets as biomarkers of coronary artery disease L Pasalic, SSY Wang, VMY Chen Seminars in thrombosis and hemostasis 42 (03), 223-233, 2016 | 41 | 2016 |
| Review and evolution of guidelines for diagnosis of COVID-19 vaccine induced thrombotic thrombocytopenia (VITT) EJ Favaloro, L Pasalic, G Lippi Clinical Chemistry and Laboratory Medicine (CCLM) 60 (1), 7-17, 2022 | 37 | 2022 |
| Replacing warfarin therapy with the newer direct oral anticoagulants, or simply a growth in anticoagulation therapy? Implications for pathology testing EJ Favaloro, L Pasalic, G Lippi Pathology 49 (6), 639-643, 2017 | 36 | 2017 |
| Enumeration of extracellular vesicles by a new improved flow cytometric method is comparable to fluorescence mode nanoparticle tracking analysis L Pasalic, R Williams, A Siupa, H Campbell, MJ Henderson, VMY Chen Nanomedicine: Nanotechnology, Biology and Medicine 12 (4), 977-986, 2016 | 36 | 2016 |
| Detection of mild inherited disorders of blood coagulation: current options and personal recommendations G Lippi, L Pasalic, EJ Favaloro Expert Review of Hematology 8 (4), 527-542, 2015 | 36 | 2015 |
| Genetic testing for thrombophilia-related genes: observations of testing patterns for factor V Leiden (G1691A) and prothrombin gene “Mutation”(G20210A) EJ Favaloro Seminars in thrombosis and hemostasis 45 (07), 730-742, 2019 | 35 | 2019 |
